LINTONPHARM
27.5.2022 15:02:13 CEST | Business Wire | Press release
LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Abstract Number：
e16102
Abstract Title：
Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis.
The abstract is about the cohort A, stage I of the ongoing global phase Ⅲ trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis (clinicaltrials.gov: NCT04222114). Worldwide, GC is one of the most common cancers, contributing to more than 1 million cases per year and 5.6% of all cancer diagnoses [1] . Approximately 50% of the advanced GC patients will develop peritoneal metastasis after radical resection, along with malignant ascites in most cases. Furthermore, peritoneal metastasis is associated with poor prognosis and quality of life compared with metastasis to other organs [2] . Peritoneal metastasis is treated with systemic therapies. The estimated survival period for the patients who fail to respond to third-line therapy is limited to only 2.3-2.4 months according to multiple RCTs.
In our study, 9 GC patients with peritoneal metastasis (33% had failed third-line therapy) were treated with Catumaxomab, the median overall survival was 3.4 months, with remarkable ascites regression. Catumaxomab as an T cell engaging immunotherapy has showed promising early efficacy signals.
About Catumaxomab
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. It is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through FcγR binding at the same time. Catumaxomab kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. Currently, Catumaxomab is being evaluated in clinical trials for both advanced gastric cancer (NCT04222114) and non-muscle invasive bladder cancer (NCT04799847).
About LintonPharm
LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. For more information, please visit www.lintonpharm.com
Reference
1. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/
2. Jennifer L.L. & Travis E.G. Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis. World J Gastrointest Oncol 2018 October 15; 10(10): 282-289.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220527005174/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
iQmetrix and Stratus HR Partner to Give Wireless Retailers a Complete, Outsourced HR Department14.10.2026 17:15:00 CEST | Press release
New integration connects the employee lifecycle to the store – new hires, terminations, rehires, position moves, and security-role updates flow straight into the POS, with payroll, benefits, and compliance handled by Stratus HR’s certified experts. Stratus HR, a full-service human resources outsourcing provider, today announced a partnership with iQmetrix, the Intelligent Commerce Operating System for telecom. As a Professional Employer Organization (PEO), Stratus HR becomes the complete, outsourced HR partner for wireless retailers on iQmetrix – payroll, benefits, compliance, and on-call HR experts – so retail teams stay focused on selling and serving customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014178512/en/ Fully integrated with iQmetrix, Stratus HR’s custom-built technology connects the employee lifecycle to the store: new hires, terminations, rehires, position moves, and security-role updates flow straig
New Study Brings Ketogenic Therapy for Bipolar Disorder Directly to Rural Alabama Homes14.10.2026 17:00:00 CEST | Press release
Leveraging Alabama’s agricultural strength, a new Baszucki Group-funded pilot study uses food bank delivery to expand metabolic psychiatry research into resource-poor rural areas Baszucki Group today announced funding for a clinical study to examine the impact of ketogenic therapy on people living with bipolar disorder in rural Central Alabama. This study, led by researchers at the University of Alabama at Birmingham Heersink School of Medicine Montgomery Regional Campus, will partner with Heart of Alabama Food Bank (HAFB), sourcing Alabama-raised meats and produce to introduce metabolic psychiatry to a region characterized by a high prevalence of serious mental illness and severe shortages in psychiatric care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014955753/en/ A new study led by Will Rutland of UAB Montgomery and funded by Baszucki Group aims to improve access to psychiatric treatment in rural areas. By partner
Ant International Obtains Key Licenses from the Central Bank of the UAE to Support Digital Payments in the AI Era14.10.2026 16:32:00 CEST | Press release
Ant International, a leading global provider of digital payments and financial technology, has secured a Retail Payment Services and Card Schemes (Category II) (RPSCS) license and Stored Value Facilities (SVF) license from the Central Bank of the UAE (CBUAE), aligning with the UAE’s broader agenda for innovation and digital transformation in the financial sector. “The RPSCS and SVF licenses mark a crucial milestone in Ant International’s efforts to support the UAE’s fintech ecosystem, aligning with the nation’s ‘We are UAE 2031’ digitalisation and fintech strategy,” said Leiming Chen, Chief Sustainability Officer and Senior Vice President of Ant International. “In accordance with the applicable CBUAE regulatory framework, we look forward to launching AI-powered global payment and account solutions to make cross-border payments and financial management more accessible." Obtaining the RPSCS license is an important step towards Antom, a leading merchant payment and digitisation services p
International Optics and Photonics Community Invited to SPIE Photonics West 202714.10.2026 16:01:00 CEST | Press release
Thousands from around the globe will share research breakthroughs and industry innovations in optics and photonics SPIE, the international society for optics and photonics, invites the global optics and photonics community to register for SPIE Photonics West 2027, happening 30 January–4 February at the Moscone Center in San Francisco, California. The dynamic week draws 24,000 researchers, engineers, students, and business leaders from around the globe, providing technical presentations, exhibitions, and networking opportunities that fuel collaboration and real-world innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013654749/en/ SPIE Photonics West will be held 30 January-4 February 2027 in San Francisco, California. The annual event brings together 24,000 people from the global optics and photonics community to foster collaboration and innovation. SPIE anticipates more than 4,500 presentations will be given acro
Toluna Appoints Amy Fenton as Chief Executive Officer14.10.2026 15:30:00 CEST | Press release
Appointment completes the planned succession announced on October 8, 2026. Founder Frédéric Charles Petit continues as Board member, Senior Advisor and Shareholder. Toluna, a global leader in consumer insights and market research technology, today announces the appointment of Amy Fenton as Chief Executive Officer, effective October 15, 2026. Ms. Fenton succeeds Frédéric Charles Petit, who founded Toluna and has led the company for 25 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014103169/en/ Amy Fenton appointed as new Chief Executive Officer, Toluna The appointment concludes the structured succession process announced on October 8, 2026, led by the Board in close consultation with Mr. Petit and supported by a leading executive search firm. Ms. Fenton brings more than 30 years of leadership experience in the insights and analytics industry. She joins Toluna from MarketCast, where she served as Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom